Welcome to our dedicated page for DFP Holdings SEC filings (Ticker: DFPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DFP Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DFP Holdings's regulatory disclosures and financial reporting.
The Oncology Institute, Inc. (TOI) furnished an investor presentation under Item 7.01 (Regulation FD) via an 8-K. The presentation, dated November 14, 2025, is attached as Exhibit 99.1. TOI states this information is furnished, not filed, so it is not subject to Section 18 liabilities and is not incorporated by reference into Securities Act or Exchange Act filings. TOI’s securities trade on Nasdaq under TOI (common stock) and TOIIW (redeemable warrants).
The Oncology Institute, Inc. (TOI) furnished an investor presentation under Item 7.01 (Regulation FD) via an 8-K. The presentation, dated November 14, 2025, is attached as Exhibit 99.1. TOI states this information is furnished, not filed, so it is not subject to Section 18 liabilities and is not incorporated by reference into Securities Act or Exchange Act filings. TOI’s securities trade on Nasdaq under TOI (common stock) and TOIIW (redeemable warrants).
The Oncology Institute, Inc. (TOI) reported Q3 2025 results with total operating revenue of $136.6 million, up from $99.9 million a year ago, driven mainly by dispensary sales. Dispensary revenue reached $75.9 million versus $48.2 million, while patient services were $60.2 million versus $49.8 million. Capitated revenue was $20.6 million versus $14.8 million.
The company posted a Q3 loss from operations of $8.1 million, improving from a $13.9 million loss, and a net loss of $16.5 million. Year‑to‑date revenue was $360.8 million with a net loss of $53.1 million. Cash and cash equivalents were $27.7 million at quarter‑end, and net cash used in operations was $27.8 million for the nine months.
TOI reduced SG&A and executed financing actions: a $20.0 million partial prepayment of its Senior Secured Convertible Notes and removal of the $40.0 million minimum cash covenant; approximately $16.5 million in gross proceeds from a private placement; and $11.8 million in aggregate gross proceeds under its at‑the‑market program, including 3.4 million shares sold in Q3. Long‑term debt was $76.2 million, and stockholders’ equity was a deficit of $12.3 million. Management concluded it has sufficient liquidity for at least one year.
The Oncology Institute, Inc. (TOI) reported Q3 2025 results with total operating revenue of $136.6 million, up from $99.9 million a year ago, driven mainly by dispensary sales. Dispensary revenue reached $75.9 million versus $48.2 million, while patient services were $60.2 million versus $49.8 million. Capitated revenue was $20.6 million versus $14.8 million.
The company posted a Q3 loss from operations of $8.1 million, improving from a $13.9 million loss, and a net loss of $16.5 million. Year‑to‑date revenue was $360.8 million with a net loss of $53.1 million. Cash and cash equivalents were $27.7 million at quarter‑end, and net cash used in operations was $27.8 million for the nine months.
TOI reduced SG&A and executed financing actions: a $20.0 million partial prepayment of its Senior Secured Convertible Notes and removal of the $40.0 million minimum cash covenant; approximately $16.5 million in gross proceeds from a private placement; and $11.8 million in aggregate gross proceeds under its at‑the‑market program, including 3.4 million shares sold in Q3. Long‑term debt was $76.2 million, and stockholders’ equity was a deficit of $12.3 million. Management concluded it has sufficient liquidity for at least one year.
The Oncology Institute, Inc. filed a current report stating that it issued a press release announcing its financial results for the three months ended September 30, 2025.
The company furnished the press release as Exhibit 99.1, which includes details about its results of operations and financial condition for the quarter, along with other financial information. The company notes that this information is being furnished rather than filed under the Exchange Act, which affects how it is treated for certain legal purposes.
The Oncology Institute, Inc. filed a current report stating that it issued a press release announcing its financial results for the three months ended September 30, 2025.
The company furnished the press release as Exhibit 99.1, which includes details about its results of operations and financial condition for the quarter, along with other financial information. The company notes that this information is being furnished rather than filed under the Exchange Act, which affects how it is treated for certain legal purposes.
The Oncology Institute (TOI) reported a third‑party cybersecurity incident affecting an external software provider that is expected to cause a brief, immaterial delay in fee‑for‑service collections. The company said there is no indication from the provider that any patient personal information was compromised, and the investigation is ongoing.
TOI is working with the provider to mitigate impacts and restore normal billing operations. The disclosure was furnished under Regulation FD.
The Oncology Institute (TOI) reported a third‑party cybersecurity incident affecting an external software provider that is expected to cause a brief, immaterial delay in fee‑for‑service collections. The company said there is no indication from the provider that any patient personal information was compromised, and the investigation is ongoing.
TOI is working with the provider to mitigate impacts and restore normal billing operations. The disclosure was furnished under Regulation FD.